Gynecological Endocrinology最新文献

{"title":"Obesity and menopause.","authors":"Santiago Palacios, Peter Chedraui, Rafael Sánchez-Borrego, Pluvio Coronado, Rossella E Nappi","doi":"10.1080/09513590.2024.2312885","DOIUrl":"10.1080/09513590.2024.2312885","url":null,"abstract":"<p><p>Obesity is not a choice or a result of lack of willpower, but a multifactorial, chronic, progressive, and relapsing disease. During menopause, hormonal and body composition changes lead to greater visceral adiposity, that aggravates women's health at a cardiometabolic, mechanic and mental level. Adiposity has been identified as an important modifier of reproductive hormones. During female midlife, obesity has been associated with menstrual cycle alterations (anovulatory cycles ending with abnormal bleedings), menopausal symptoms including hot flashes, poor quality of sleep, aches and joint pain, genitourinary symptoms, and reduced quality of life. However, the relationships between weight, the menopausal process, aging, and hormone levels remain poorly understood. Women with obesity have an increased risk of thromboembolic disease when using menopause hormone therapy (MHT), and it is probably the main medical condition to prescribe or not MHT. However, this risk depends on the route and type of MHT. The use of estrogen-only or combined transdermal MHT does not increase the risk of a thrombotic event in women with obesity.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2312885"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of androgen levels on serum metabolic profiles in patients with polycystic ovary syndrome.","authors":"Zhao Ting, Tao Xinghua, Xiao Xiao, Li Lingchuan, Wu Xiaomei, Yuan Tao","doi":"10.1080/09513590.2024.2352136","DOIUrl":"https://doi.org/10.1080/09513590.2024.2352136","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the impact of serum androgen levels on metabolic profiles in patients with polycystic ovary syndrome (PCOS).</p><p><strong>Methods: </strong>We included 216 patients with PCOS and 216 healthy individuals selected as the control group. According to the measured serum androgen levels, patients with PCOS were divided into the hyperandrogenism group and non-hyperandrogenism group. Clinical metabolic indicators were assessed and compared between the two groups. Additionally, we assessed the correlation between androgen levels and clinical metabolic indicators.</p><p><strong>Results: </strong>The body mass index, waist-to-hip ratio, mF-G score, and acne score, as well as T, LH, LSH/FSH, FPG, Cr, UA, TG, TC, and LDL-C levels were significantly higher in the PCOS group than in the control group. The incidence of hyperandrogenism and clinical hyperandrogenism in the PCOS group was significantly higher than that in the control group. Regarding clinical hyperandrogenism, hirsutism, acne, and acanthosis nigricans were significantly more common in the PCOS group than in the control group. Serum androgen levels were significantly correlated with the mF-G score, acne score, FSH, glucose concentration at 30 min, glucose concentration at 60 min, glucose concentration at 120 min, FINS, N120, HOMA-IR, HbA1c, AUCG, UA, TG, and hHDL-Clevels.</p><p><strong>Conclusion: </strong>Elevated serum androgen levels are commonly observed in patients with PCOS and are associated with multiple metabolic abnormalities. Therefore, it is recommended to regularly monitor glucose and lipid metabolism-related indicators in patients with PCOS who have elevated androgen levels.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2352136"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statement of Retraction: Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial.","authors":"","doi":"10.1080/09513590.2024.2349424","DOIUrl":"https://doi.org/10.1080/09513590.2024.2349424","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2349424"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classic congenital adrenal hyperplasia with unilateral functional adrenal cortical adenoma: case report.","authors":"Qin Yan, Huancheng Su, Xuan Jing, Sufen Li, Xujiao Ji, Zhiping Zhang, Yanni Wang, Xia Huang, Tingting Xue, Xueqing Wu, Xiangrong Cui","doi":"10.1080/09513590.2024.2373741","DOIUrl":"https://doi.org/10.1080/09513590.2024.2373741","url":null,"abstract":"<p><p>Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders related to adrenal steroid biosynthesis, and mainly caused by mutations in the CYP21A2 gene encoding 21-hydroxylase. Adrenal tumors are common in CAH, but functional adrenal tumors are rare. Here, we report a 17-year-old female with virilized external genitalia and primary amenorrhea, accompanied by a right adrenal tumor. Her 17-OHP level was normal, cortisol and androgen levels were significantly elevated, and the tumor pathology showed adrenal cortical adenoma. Gene testing for CYP21A2 showed c.518T > A in exon 4 and c.29313C > G in intron 2. The possibility of untreated classic CAH with 21-OH deficiency causing functional adrenal cortical adenoma should be considered. When clinical diagnosis highly considers CAH and cannot rule out the influence of functional adrenal tumors' secretion function on 17-OHP, gene mutation analysis should be performed.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2373741"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive interaction of pre-pregnancy BMI and assisted reproductive technology on the risk of pregnancy-induced hypertension.","authors":"Liting Wu, Feifei Chen, Miaomiao Chen, Yaping Hu, Ying Wang","doi":"10.1080/09513590.2024.2433136","DOIUrl":"https://doi.org/10.1080/09513590.2024.2433136","url":null,"abstract":"<p><strong>Objective: </strong>To explore the combined effect of pre-pregnancy body mass index (BMI) and assisted reproductive technology (ART) on the risk of pregnancy-induced hypertension (PIH).</p><p><strong>Methods: </strong>This retrospective cohort study included 3,220,103 women with singleton pregnancies from the National Vital Statistics System database for 2021. The outcome was the occurrence of PIH. Logistic regression analyses were utilized to assess the association between pre-pregnancy BMI and ART and PIH. To evaluate the interaction of pre-pregnancy BMI and ART on PIH, the relative excess risk of interaction (RERI), the attributable proportion due to interaction (API), and synergy index (SI) were applied.</p><p><strong>Results: </strong>Of these 3,220,103 women, 302,789 [9.40% (95%CI: 9.37%-9.43%)] occurred PIH. Women with a pre-pregnancy BMI ≥25 kg/m² [odds ratio (OR)=2.06, 95% confidence interval (CI): 2.04-2.08] or using ART (OR = 1.43, 95%CI: 1.39-1.47) were related to a higher risk of PIH. There was a positive additive interaction of pre-pregnancy BMI and ART on the risk of PIH, with an interaction RERI, API, and SI of 0.20 (95%CI: 0.08-0.33), 0.07 (95%CI: 0.03-0.11), and 1.13 (95%CI: 1.05-1.21), respectively. Stratified analyses demonstrated that the positive additive interactions of pre-pregnancy BMI and ART on PIH were observed in women aged <35 years or ≥35 years and in women with unipara or multipara, whereas only in White women.</p><p><strong>Conclusion: </strong>A positive additive interaction of pre-pregnancy BMI and ART on the risk of PIH was found, with an interaction of 7%.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2433136"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and methodology of the 'endometriosis and pelvic floor dysfunction' (EndoPFD) multicenter cross-sectional study.","authors":"Eleonora Russo, Maria F Brancalion, Tiziana Fidecicchi, Maria M Montt-Guevara, Giulia Misasi, Clara Baroni, Riccardo Morganti, Cristina Zito, Elena Pisacreta, Sara Gorini, Alessandro Sturiale, Giorgio Pomara, Jessica Ottolina, Andrea Scalera, Angela Maria Di Puoti, Salvatore Tolone, Gaetano Scalzone, Marco Torella, Stefano Salvatore, Tommaso Simoncini","doi":"10.1080/09513590.2024.2432479","DOIUrl":"10.1080/09513590.2024.2432479","url":null,"abstract":"<p><strong>Objective: </strong>To assess the prevalence and the characteristics of pelvic floor dysfunction (PFD) in women with endometriosis.</p><p><strong>Methods: </strong>This is a methodological paper that describes the 'Endometriosis and Pelvic Floor Dysfunction' (EndoPFD) multicenter study protocol. It involves three sites: the University Hospital of Pisa, the San Raffaele Hospital of Milan and the Vanvitelli University Hospital of Naples. Women are recruited through web links and are asked whether they want to participate to the clinical evaluation or only to the web survey. The web survey gathers personal history, endometriosis history and symptoms, and performs a subjective evaluation of PFD through questionnaires: Urinary Distress Inventory 6, Colorectal-Anal Distress Inventory 8, Wexner Scale for Fecal Incontinence, Wexner Constipation Scoring System, and Female Sexual Function Index. Those interested in the clinical evaluation will add to the questionnaires the following exams: gynecological and proctological exam, pelvic ultrasound, urodynamic test, and anorectal manometry.</p><p><strong>Preliminary results: </strong>Recruitment for the web survey was completed. A total of 1,149 women signed the electronic consent, 329 were excluded due to inclusion/exclusion criteria; hence, 525 completed all the questionnaires (response rate of 64.02%). Recruitment for the clinical evaluation is ongoing.</p><p><strong>Discussion: </strong>This study protocol offers the possibility to define the prevalence of PFD in endometriosis patients with a subjective and an objective assessment of signs and symptoms. This may pave the way for changing the approach to patients with endometriosis. Moreover, it demonstrates the validity of the method used (online survey and recruitment) to reach a high number of patients.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2432479"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression and clinical significance of lncRNA PART1 in patients with unexplained recurrent pregnancy loss.","authors":"Chen Lihua, Su Hua, Wang Wenzhan, Jeson Standard, Liang Denghui","doi":"10.1080/09513590.2024.2375582","DOIUrl":"https://doi.org/10.1080/09513590.2024.2375582","url":null,"abstract":"<p><strong>Purpose: </strong>Previous studies have reported the involvement of long noncoding RNAs (lncRNAs) in reproductive diseases <i>via</i> the regulation of target genes. This study aimed to determine whether lnc-prostate androgen-regulated transcript 1 (lnc-PART1)could be used as a biomarker of unexplained recurrent pregnancy loss (URPL) and a possible predictor of poor pregnancy outcomes in women with URPL.</p><p><strong>Materials and methods: </strong>Sixty patients with URPL and 15 healthy women were included in this study. PART1 expression was detected in plasma and endometrial tissues using a quantitative reverse transcription polymerase chain reaction. Logistic regression and receiver operating characteristic curve analyses were performed to analyze the association between PART1 expression and pregnancy outcomes in women with URPL.</p><p><strong>Results: </strong>The expression of PART1transcript variant 2 was significantly up-regulated in the endometrial specimens from patients with URPL compared to control tissues. High tissue expression levels of PART1transcript variant 2 were associated with poor pregnancy outcomes in women with URPL, indicating that it could serve as a potential risk factor. Additionally, PART1 could serve as a potential risk factor for adverse pregnancy outcomes in patients with URPL (OR = 4.374; 95% CI = 1.052-18.189; <i>p</i> = .042).</p><p><strong>Conclusion: </strong>lncRNA PART1 transcript variant 2 was highly expressed in patients with URPL. Therefore, it is important to conduct in-depth studies on the relationship between PART1 expression and URPL.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2375582"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effects of the antioxidant glutathione with metformin and Diane-35 on hormonal, metabolic, and inflammatory indicators in a DHEA-induced PCOS rat model.","authors":"Aslı Coşar, Pınar Özcan, Fatma Basak Tanoglu, Olgu Enis Tok, Gülçin Özkara, Hikmet Tunç Timur, Çağlar Çetin, Duygu Neccar","doi":"10.1080/09513590.2024.2302086","DOIUrl":"10.1080/09513590.2024.2302086","url":null,"abstract":"<p><strong>Objective: </strong>Comparison of hormonal, metabolic and inflammatory markers of glutathione with metformin and Diane-35 in a rat model of PCOS induced by dehydroepiandrosterone.</p><p><strong>Methods: </strong>Twenty-five female rats were randomized into four groups. Group 1 was administered a subcutaneous dose of 0.2 ml saline/day. Group 2 was given 0.2 ml of 1% carboxymethyl cellulose (CMC)/day orally for 28 days. A PCOS model was established with DHEA in rats. Group 3 was given 4.5 mg/kg/day of Diane-35 orally dissolved in 1% CMC for 28 days. Group 4 was given 300 mg/kg/day of metformin orally dissolved in 1 ml of saline for 28 days, and Group 5 was administered 100 mg/kg of glutathione intraperitoneally on days 35, 42, and 49. On day 56, the rats were sacrificed. Serum markers and follicle count were examined.</p><p><strong>Results: </strong>Serum IL-6, hs-CRP, insulin, testosterone, SHBG, and MDA values were significantly lower in the glutathione group than in the PCOS group (<i>p</i> = 0.0006, <i>p</i> = 0.023, <i>p</i> = 0.0082, <i>p</i> = 0.0007, <i>p</i> = 0.0048, and <i>p</i> < 0.0001, respectively).The number of all follicles was similar between the control and glutathione groups (<i>p</i> < 0.05). When we compared the other groups with the PCOS group, the number of primary, secondary, atretic, and cystic follicles was significantly lower in the metformin and glutathione groups. The number of primordial and antral follicles was significantly higher than in the PCOS group.</p><p><strong>Conclusions: </strong>Glutathione plays anti-inflammatory and antioxidant roles, similar to metformin, by lowering serum IL-6, insulin, testosterone, CRP, and MDA levels; decreasing atretic/cystic follicle count; and improving antral follicle count and folliculogenesis in PCOS patients.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2302086"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statement of Retraction: Combined metformin and clomiphene citrate <i>versus</i> highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial.","authors":"","doi":"10.1080/09513590.2023.2272094","DOIUrl":"10.1080/09513590.2023.2272094","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":" ","pages":"2272094"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71480836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of body mass index on progesterone level on trigger day in gonadotropin-releasing hormone antagonist cycles.","authors":"Yating Sun, Aizhen Zhu","doi":"10.1080/09513590.2024.2364892","DOIUrl":"https://doi.org/10.1080/09513590.2024.2364892","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of body mass index (BMI) on progesterone (P) level on trigger day in gonadotropin-releasing hormone antagonist (GnRH-ant) cycles.</p><p><strong>Methods: </strong>This study was a retrospective cohort study. From October 2017 to April 2022, 412 <i>in-vitro</i> fertilization (IVF)/intracytoplasmic sperm injection (ICSI) patients who were treated with GnRH-ant protocol for controlled ovarian hyperstimulation (COH) in the reproductive center of our hospital were selected as the research objects. Patients were divided into three groups according to BMI level: normal weight group (<i>n</i> = 230):18.5 kg/m²≤BMI < 24 kg/m²; overweight group (<i>n</i> = 122): 24 kg/m²≤BMI < 28 kg/m²; Obesity group (<i>n</i> = 60): BMI ≥ 28 kg/m². Variables with <i>p</i> < .10 in univariate analysis (BMI, basal FSH, basal P, FSH days, Gn starting dose and E₂ level on trigger day) and variables that may affect P level on trigger day (infertility factors, basal LH, total FSH, HMG days and total HMG) were included in the multivariate logistic regression model to analyze the effect of BMI on P level on trigger day of GnRH-ant protocol.</p><p><strong>Results: </strong>After adjustment for confounding factors, compared with that in normal weight patients, the risk of serum P elevation on trigger day was significantly lower in overweight and obese patients (OR = 0.434 and 0.199, respectively, <i>p</i> < .05).</p><p><strong>Conclusion: </strong>The risk of P elevation on trigger day in GnRH-ant cycles decreased with the increase of BMI, and BMI could be used as one of the predictors of P level on trigger day in GnRH-ant cycles.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2364892"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}